Skip to main content
Equibles

COHANCE · Cohance Lifesciences Limited · Documents

Use COHANCE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research COHANCE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
458.55 INR -13.00 (-2.76%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 33.93K Avg daily vol (3M) 146.33K

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Earnings call New Q2 2027 earnings call Held Nov 6, 2026
2026
Nov 6
Earnings call
Revenue rises 13% sequentially, adjusted EBITDA reaches 458 million

Cohance reported revenue increasing 13% sequentially to 4767 million and adjusted EBITDA of 458 million, with margin improving to 10%. Management expects HALF 2 of FY27 year-on-year revenue and EBITDA growth, while assessing the Surya Paik closure order.

4 source passages
Revenue increased 13% sequentially to 4767 million. While adjusted EBITDA increased to 458 million, with the adjusted EBITDA margin improving to 10%. Based on the visibility we have today, we continue to expect HALF 2 of FY27 to deliver year-on-year growth on both revenue and EBITDA. At this stage, we are also assessing any further impact from the Surya Paik closure order. At Cohance, right, we have a good relation with several large pharmaceutical customers Open the document at this passage
Showing 1–3 of 3 documents